[Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)].
作者信息
Kohno Shigeru, Watanabe Akira, Mikasa Kechi, Asano Kazunori
出版信息
Jpn J Antibiot. 2003 Apr;56(2):93-104.
PMID:12825412
Abstract
摘要
相似文献
1
[Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)].
Jpn J Antibiot. 2003 Apr;56(2):93-104.
2
[A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections].
Antibiot Khimioter. 2001;46(6):38-42.
3
Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
Expert Opin Investig Drugs. 2003 Jul;12(7):1165-77. doi: 10.1517/13543784.12.7.1165.
4
[Use of new quinolones in respiratory infections].
Rev Clin Esp. 2000 Dec;200(12):682-4.
5
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
Clin Infect Dis. 2000 Aug;31 Suppl 2:S16-23. doi: 10.1086/314054.
6
Newer fluoroquinolones and the management of respiratory tract infections.
Clin Infect Dis. 2000 Aug;31 Suppl 2:S15. doi: 10.1086/314055.
7
Role of newer fluoroquinolones in lower respiratory tract infections.
J Antimicrob Chemother. 2002 May;49(5):709-12. doi: 10.1093/jac/dkf024.
8
Role of newer fluoroquinolones in lower respiratory tract infections.
J Antimicrob Chemother. 2002 Jul;50(1):151-4. doi: 10.1093/jac/dkf133.
9
Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
J Antimicrob Chemother. 1997 Dec;40 Suppl A:99-101. doi: 10.1093/jac/40.suppl_1.99.
10
Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
Expert Opin Pharmacother. 2001 Feb;2(2):317-35. doi: 10.1517/14656566.2.2.317.
Zotero 插件